BriaCell Therapeutics Corp (C:BCT)
Shares Issued 84,736,315
Last Close 4/11/2016 $0.24
Tuesday April 12 2016 - News Release
Dr. Markus Lacher reports
BRIACELL FILES A PATENT APPLICATION TO PROTECT ADDITIONAL CANCER VACCINES WITH GENETIC FEATURES THOUGHT TO PROMOTE STRONG ANTI-TUMOR ACTIVITY
BriaCell Therapeutics Corp. has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to improve clinical efficacy of whole-cell cancer vaccines.
The patent application, entitled "WHOLE-CELL CANCER VACCINES EXPRESSING IMMUNE STIMULATORS", is based on molecular analyses of both the Company's lead anti-cancer product candidate, BriaVax{A ™}, and blood samples collected from patients treated with BriaVax{A ™} in a previous Phase I clinical study. BriaCell has identified a "gene signature" in BriaVax{A ™} that seems consistent with its strong anti-tumor activity observed at multiple sites including the breast, the lungs, and the brain in a patient who had failed prior cancer treatments.
Cancer vaccines are designed to stimulate the immune system to recognize and destroy the patient's tumors. The set of genes, or "gene signature", identified by BriaCell, may be unique in promoting these strong anti-tumor immune responses. The patent application, in essence, seeks protection for cell line-derived vaccines expressing genes of the "gene signature" and methods of use for such vaccines.
"This patent application represents a significant milestone in our efforts to understand how BriaVax{A ™} exerts its anti-tumor activity, and, more importantly, it contains information on what to look out for if we were to generate additional cancer vaccines," said Dr. Markus Lacher, BriaCell's Head of R&D. "The discovery of the gene signature in BriaVax{A ™} is a key step to developing BriaDx{A ™}, a companion diagnostic test for identifying the patients who are most likely to benefit from BriaVax{A ™} treatments. By identifying and treating such patients, we intend to bring hope to many cancer patients with few or no therapeutic options."
Presentation of data at AACR
BriaCell plans to present its findings on the aforementioned research, mechanism of action of its cancer vaccine BriaVax{A ™}, at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on April 18, 2016.
BriaCell is interested in partnership opportunities for its proprietary technology platform with other biotechnology /pharmaceutical companies. Additionally, BriaCell is exploring collaboration opportunities with investigators and clinical sites for potential combination treatment options for various cancer indications.
We seek Safe Harbor.
© 2016 Canjex Publishing Ltd. |
